Day: May 6, 2024

CINCINNATI, May 06, 2024 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal second quarter 2024 financial results on Wednesday, May 15, 2024. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Thursday, May 16, 2024, at 10:00 a.m. (ET). The call-in numbers for participants are:  Canada/US Toll Free: 1 (844) 763 8274  International: 1 (647) 484 8814     A live webcast of the call will be accessible via the investor section of the Company’s website through the following link: www.quipthomemedical.com. ABOUT QUIPT HOME MEDICAL The Company provides in-home monitoring and disease management...

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) — Metasphere Labs Inc. (“Metasphere” or the “Company“) (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is delighted to announce a follow-up event tailored for those who were unable to attend the initial sessions, in response to the overwhelming demand and overcapacity of our recent seminar on Bitcoin’s DeFi revolution. Additionally, the Company excited to open limited registration spots for new registrants eager to delve into the world of decentralized finance on the Bitcoin network. Interested individuals can sign up at the following URL: https://metasphere.earth/bitcoin-defi-seminar. Since the inception of the Company’s previous seminar, the interest and enthusiasm surrounding Bitcoin’s evolving capabilities have only intensified. It’s...

LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross proceeds from the offering, before deducting the underwriting discount and offering expenses payable by the Company and assuming no exercise of the pre-funded warrants, are expected to be approximately $105.0 million. The offering is expected to close on May 8, 2024, subject to customary closing conditions. Jefferies, Guggenheim Securities and...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Conference Fireside Chat Date: Monday, May 13, 2024 Fireside Chat Time: 1:00 PM ET Location: New York, NY BofA Securities 2024 Health Care Conference Fireside Chat Date: Wednesday, May 15, 2024 Fireside Chat Time: 3:00 PM PTLocation: Las Vegas, NV A live webcast of the fireside chats at the Citizens JMP Life Sciences Conference and BofA Securities...

Dime continues to execute on growth plan HAUPPAUGE, N.Y., May 06, 2024 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced that it has hired a deposit-focused Group that will cover the Williamsburg market. The Group will be led by John McDonough and Emanuel “Manny” Diconimakis. The Group was previously employed with the former Signature Bank and its successor, Flagstar Bank. Stuart H. Lubow, President and Chief Executive Officer of Dime said, “We are excited to announce the addition of another talented deposit-focused Group in the strategically important market of Brooklyn. Dime, which was founded in Williamsburg in 1864, has always been a key part of the fabric of this vibrant neighborhood. It gives us great satisfaction...

MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps. Dear Friends, The last few days have been very difficult. I received a lot of emails and phone calls that often expressed anger, uncertainty, and disappointment. Additionally, our results were questioned and criticized. This reaction not only caused a drastic drop in our share price, but, more importantly, it saddened the Annovis team. We are determined to develop a drug that treats Alzheimer’s (AD) and Parkinson’s diseases (PD) and...

Year-Over-Year Growth in Operating Income Highlights Progress on Strategic Initiatives SPRINGDALE, Ark., May 06, 2024 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:                                         (in millions, except per share data) Second Quarter   Six Months Ended    2024     2023       2024     2023Sales $         13,072   $         13,133     $         26,391   $         26,393Operating Income (Loss) $         312   $         (49 )   $         543   $         418Adjusted1 Operating Income (non-GAAP) $         406   $         65     $         817   $         518Net Income (Loss)...

$6.5 million in upfront gross proceeds with the potential to receive up to an additional $11.5 million in potential warrant exercise proceeds for an aggregate of up to approximately $18 million in total gross proceeds AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement with new institutional investors and Company insiders to raise up to approximately $18 million in gross proceeds, including initial upfront funding of approximately $6.5 million, and up to an additional approximately $11.5 million upon cash exercise of accompanying warrants at the election...

•   105 patients enrolled •   April represents a record breaking month for patient enrollment  TORONTO, May 06, 2024 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment:Robust enrollment activity continuing throughout 2024:105 patients enrolled at end of April 2024Record monthly enrollment with seven patients enrolled in April 24 patients enrolled in 2024 so far – represents the most robust enrollment rates since the start of the Tigris studyWith 45 patients to full...